JP2008518999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518999A5 JP2008518999A5 JP2007539549A JP2007539549A JP2008518999A5 JP 2008518999 A5 JP2008518999 A5 JP 2008518999A5 JP 2007539549 A JP2007539549 A JP 2007539549A JP 2007539549 A JP2007539549 A JP 2007539549A JP 2008518999 A5 JP2008518999 A5 JP 2008518999A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- phenyl
- optionally substituted
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000217 alkyl group Chemical group 0.000 claims 121
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 70
- 125000000623 heterocyclic group Chemical group 0.000 claims 69
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 65
- 229910052736 halogen Inorganic materials 0.000 claims 56
- 150000002367 halogens Chemical class 0.000 claims 56
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 29
- 229910052799 carbon Inorganic materials 0.000 claims 22
- -1 —CH═CH 2 Chemical group 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 13
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 10
- 125000001624 naphthyl group Chemical group 0.000 claims 10
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 claims 9
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 9
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 2
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 claims 2
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 claims 2
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 claims 2
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 claims 1
- FKNNFFNBSFNFSP-UHFFFAOYSA-N 2-hydroxy-5-[2,2,2-trichloro-1-[(4-chlorophenyl)sulfonylamino]ethyl]benzamide Chemical compound C1=C(O)C(C(=O)N)=CC(C(NS(=O)(=O)C=2C=CC(Cl)=CC=2)C(Cl)(Cl)Cl)=C1 FKNNFFNBSFNFSP-UHFFFAOYSA-N 0.000 claims 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 claims 1
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 229940123324 Acyltransferase inhibitor Drugs 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229940126033 PPAR agonist Drugs 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 102000014743 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 claims 1
- 108010064032 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Proteins 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000002404 acyltransferase inhibitor Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002720 diazolyl group Chemical group 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 208000037765 diseases and disorders Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229940121380 ileal bile acid transporter inhibitor Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229960004738 nicotinyl alcohol Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 230000021148 sequestering of metal ion Effects 0.000 claims 1
- 125000000565 sulfonamide group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04026441A EP1655283A1 (en) | 2004-11-08 | 2004-11-08 | 11beta-HSD1 Inhibitors |
PCT/EP2005/011933 WO2006048330A1 (en) | 2004-11-08 | 2005-11-08 | 11βετα-hsd1 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008518999A JP2008518999A (ja) | 2008-06-05 |
JP2008518999A5 true JP2008518999A5 (US07928230-20110419-C00074.png) | 2008-12-25 |
Family
ID=34927280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007539549A Abandoned JP2008518999A (ja) | 2004-11-08 | 2005-11-08 | 11β−HSD1阻害剤 |
Country Status (7)
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
BRPI0606256A2 (pt) | 2005-01-05 | 2009-06-09 | Abbott Lab | inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
WO2006074330A2 (en) | 2005-01-05 | 2006-07-13 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2007067817A1 (en) * | 2005-12-07 | 2007-06-14 | Cv Therapeutics, Inc. | Abca1 elevating compounds |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
WO2007138112A2 (en) * | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
US9422235B2 (en) | 2006-12-19 | 2016-08-23 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2010059618A1 (en) | 2008-11-21 | 2010-05-27 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
CN101838227A (zh) * | 2010-04-30 | 2010-09-22 | 孙德群 | 一种苯甲酰胺类除草剂的安全剂 |
US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
WO2012051117A2 (en) * | 2010-10-11 | 2012-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Substituted benzamides and their uses |
RU2612959C2 (ru) | 2011-02-18 | 2017-03-14 | АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи | Аминоиндановые соединения и их применение при лечении боли |
CN103732589B (zh) | 2011-05-25 | 2016-03-30 | 百时美施贵宝公司 | 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺 |
WO2013112323A1 (en) | 2012-01-23 | 2013-08-01 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors |
ES2571577T3 (es) | 2012-01-31 | 2016-05-26 | Lilly Co Eli | Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2 |
TW201343629A (zh) | 2012-01-31 | 2013-11-01 | Lilly Co Eli | 可作為mogat-2抑制劑之新穎芐磺醯胺衍生物 |
WO2014028675A1 (en) | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
AU2013341584A1 (en) | 2012-11-06 | 2015-04-30 | Eli Lilly And Company | Novel benzyl sulfonamide compounds useful as MoGAT-2 inhibitors |
MX2017014956A (es) | 2015-06-03 | 2018-04-13 | Squibb Bristol Myers Co | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. |
US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
SI3571193T1 (sl) | 2017-01-23 | 2022-04-29 | Cadent Therapeutics, Inc. | Modulatorji kalijevega kanalčka |
KR20200094734A (ko) | 2017-09-22 | 2020-08-07 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 헤테로사이클릭 화합물 |
DK3697785T3 (da) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidazo-pyridine forbindelser som pad-inhibitorer |
AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
CA3083374A1 (en) | 2017-11-24 | 2019-05-31 | Jubilant Episcribe Llc | Heterocyclic compounds as prmt5 inhibitors |
AU2019234185A1 (en) | 2018-03-13 | 2020-10-01 | Jubilant Prodel LLC. | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
JP2022508945A (ja) | 2018-10-22 | 2022-01-19 | カデント セラピューティクス,インコーポレーテッド | カリウムチャネルモジュレーターの結晶形態 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0206219D0 (en) * | 2002-03-15 | 2002-05-01 | Ferring Bv | Non-Peptide GnRH antagonists |
US20060058315A1 (en) * | 2002-11-07 | 2006-03-16 | Astrazeneca Ab | 2-Oxo-ethanesulfonamide derivates |
-
2004
- 2004-11-08 EP EP04026441A patent/EP1655283A1/en not_active Withdrawn
-
2005
- 2005-11-08 DE DE602005013812T patent/DE602005013812D1/de active Active
- 2005-11-08 AT AT05806462T patent/ATE427932T1/de not_active IP Right Cessation
- 2005-11-08 EP EP05806462A patent/EP1814846B1/en not_active Not-in-force
- 2005-11-08 DK DK05806462T patent/DK1814846T3/da active
- 2005-11-08 JP JP2007539549A patent/JP2008518999A/ja not_active Abandoned
- 2005-11-08 US US11/667,114 patent/US20090069323A1/en not_active Abandoned
- 2005-11-08 WO PCT/EP2005/011933 patent/WO2006048330A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008518999A5 (US07928230-20110419-C00074.png) | ||
RU2500673C2 (ru) | Гетероциклические ингибиторы мек и способы их применения | |
CA2502269A1 (en) | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
JP2006510630A5 (US07928230-20110419-C00074.png) | ||
Emmitte | mGlu5 negative allosteric modulators: a patent review (2010–2012) | |
RU2454411C2 (ru) | Производные хинолина | |
Phillips et al. | Discovery of trifluoromethyl (pyrimidin-2-yl) azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure–activity relationships, lead optimization, and chronic in vivo efficacy | |
RU2006134004A (ru) | Производные гетероариламинопиразола, пригодные для лечения диабета | |
AR054848A1 (es) | Agonistas del receptor de la hormona tiroidea | |
AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
AU2018253864A1 (en) | Ferroportin-inhibitor salts | |
CA2593264A1 (en) | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
JP2004536115A5 (US07928230-20110419-C00074.png) | ||
RU2011102560A (ru) | Соединение карбоновой кислоты | |
JP2010520893A5 (US07928230-20110419-C00074.png) | ||
CA2522435A1 (en) | Inhibitors of akt activity | |
JP2007507551A5 (US07928230-20110419-C00074.png) | ||
JP2010523653A5 (US07928230-20110419-C00074.png) | ||
ZA200606870B (en) | Oxadiazolone derivatives as PPAR delta agonists | |
RU2006140796A (ru) | Ингибиторы дпп-iv | |
KR20190020170A (ko) | 통풍 또는 고뇨산혈증과 관련된 증상의 치료 또는 예방을 위한 화합물, 조성물 및 방법 | |
JP2011521938A5 (US07928230-20110419-C00074.png) | ||
CA2626402A1 (en) | Potassium channel inhibitors | |
TW200920361A (en) | Compounds useful as medicaments | |
JP2017508795A5 (US07928230-20110419-C00074.png) |